Details

Autor(en) / Beteiligte

• Gasparetto, Cristina
• Jagannath, Sundar
• Rifkin, Robert M.
• Durie, Brian G.M.
• Narang, Mohit
• Terebelo, Howard R.
• Toomey, Kathleen
• Hardin, James W.
• Wagner, Lynne
• Ailawadhi, Sikander
• Omel, James L.
• Srinivasan, Shankar
• Dhalla, Mazaher
• Catamero, Donna
• Kitali, Amani
• Agarwal, Amit
• Abonour, Rafat

Titel

Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry

Ist Teil von

• Clinical lymphoma, myeloma and leukemia, 2022-03, Vol.22 (3), p.149-157

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• The t (11;14) (q13;32) translocation [t (11;14)] is present in ∼20% of patients with newly diagnosed multiple myeloma (NDMM), but studies examining its prognostic ability have yielded divergent results, and data are lacking on outcomes from first-line therapy. Data from the Connect MM Registry, a large US, multicenter, prospective observational cohort study of patients with NDMM were used to examine the effect of t (11;14) status on first-line therapy outcomes in the Overall population (n = 1574) and race groups (African American [AA] vs. non-African American [NAA]). Baseline characteristics were generally similar between patients with (n = 378) and without (n = 1196) t (11;14). Prevalence of t (11;14) was similar by race (AA, 27%; NAA, 24%). In the overall population, regardless of first-line therapy, t (11;14) status did not affect progression-free survival (hazard ratio, 1.02; P = 0.7675) or overall survival (hazard ratio, 0.99; P = .9417). AA patients with t (11;14) had higher likelihood of death (Nominal Cox regression P = .0298) vs. patients without t (11;14). Acknowledging observational study and inferential limitations, this exploratory analysis of a predominantly community-based population suggests that t (11;14) is a neutral prognostic factor in the general MM population but may be a negative factor for overall survival in AA patients. Connect MM Registry is a large, US, multicenter (84% community-based), prospective observational cohort study where the effect of t (11;14) status on first-line therapy outcomes was examined in the newly diagnosed multiple myeloma population. Exploratory analysis results suggest t (11;14) is a neutral prognostic factor in the overall population but may negatively affect overall survival in African American patients.